



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Service
Prior Authorization Criteria

CINRYZE® & HAEGARDA®
(human C1-inhibitor)
Effective 1/01/2018

Prior Authorization Request Form

CINRYZE and **HAEGARDA** are plasma-derived concentrates of C1 esterase inhibitor (human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema Attacks (HAE) in adolescent and adult patients.

CRITERIA FOR APPROVAL

- 1) The diagnosis of hereditary angioedema (HAE) has been clinically established by, or in consultation with, an allergist or immunologist; **AND**
 - 2) Patient must be 12 years or older; **AND**
 - 3) Diagnosis of HAE is documented based on evidence of low C4 level **AND** one of the following:
 - a. A low C1 inhibitor (C1-INH) antigenic level; **OR**
 - b. A normal C1-INH antigenic level and a low C1-INH functional level.
- AND**
- 4) The member has a history of more than one moderate to severe attack per month (i.e. swelling of the face, throat, or abdomen); **AND**
 - 5) Baseline frequency of HAE attacks must be documented; **AND**
 - 6) The member is not concurrently taking an angiotensin converting enzyme (ACE) inhibitor or estrogen replacement therapy; **AND**
 - 7) The recipient has had an insufficient response or contraindication to therapy with a 17 α – alkylated androgen (e.g. danazol, stanozolol, oxandrolone, methyltestosterone). **This requirement is waived for growing children and for pregnant or lactating females.**

Approvals are for 6 months

CONTINUATION OF THERAPY CRITERIA

Medical records documenting a decrease of at least 50% in the frequency of attacks and significant improvement in severity and duration of attacks must be provided.



**STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES**



REFERENCES

- 1) Cinryze package insert 12/2016
- 2) Haegarda package insert rev 06/2017
- 3) Lexi-Comp Clinical Application 11/12/2017
- 4) UpToDate Articles accessed 11/12/17: Hereditary Angioedema and Pathogenesis; Hereditary Angioedema- General Care and Long-term Prophylaxis
- 5) US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency; J ALLERGY CLIN IMMUNOL: IN PRACTICE VOLUME 1, NUMBER 5